PanOptica, Inc.

While it is human nature to expect a CEO of a company that has been successful to go on to repeat their triumphs, success may be down to luck or turn out to be elusive in more challenging assignments.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. PanOptica Confirms Deal With Zhaoke For

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

VEGF inhibitors like Lucentis (ranibizumab) have made significant inroads into treating back-of-the-eye diseases like wet age-related macular degeneration (AMD), but there are drawbacks to such ther